Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReNEW phase 3 trial of subcutaneous elamipretide in dry age-related macular degeneration
2024-511482-11-00Phase 3Authorised
- Sponsor
- Stealth BioTherapeutics
- Start
- Nov 2024
- Modality
- Peptides
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in age-related macular degeneration (AMD) comparing Elamipretide with Placebo (2 arms). Primary endpoint: Rate of change in macular photoreceptor loss. Planned start Nov 2024; status: authorised.
02
Drugs
elamipretide
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2024-511482-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511482-11-00.